Listed

Moderna, Inc.

MRNANasdaqCIK 1682852HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$145.0mRevenue, Q2 FY2026, three months to 2026-06-30$145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 31, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$145.0mRevenue, Q2 FY2026, three months to 2026-06-30$145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure+2.1% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating margin−562.1%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$815.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure+76.7 pts on a year earlier
  • Net margin−539.3%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$782.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure+41.7 pts on a year earlier
  • Diluted EPS−$1.97Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure+7.5% on a year earlier
  • Free cash flow−$563.0mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$526.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Report this figure+38.9% on a year earlier

Last eight quarters

Full statements
Revenue$145.0mOperating margin −562.1%
Diluted EPS−$1.97, Q2 FY2026
Free cash flow−$563.0m, Q2 FY2026
Moderna, Inc., key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m1,862Revenue, Q3 FY2024, three months to 2024-09-30$1.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure966Revenue, Q4 FY2024, three months to 2024-12-31$966.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure108Revenue, Q1 FY2025, three months to 2025-03-31$108.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure142Revenue, Q2 FY2025, three months to 2025-06-30$142.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure1,016Revenue, Q3 FY2025, three months to 2025-09-30$1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure678Revenue, Q4 FY2025, three months to 2025-12-31$678.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure389Revenue, Q1 FY2026, three months to 2026-03-31$389.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure145Revenue, Q2 FY2026, three months to 2026-06-30$145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%(3.8%)Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: −$70.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Revenue: $1.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure(129.0%)Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: −$1.25bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Revenue: $966.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(972.2%)Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: −$1.05bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Revenue: $108.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(638.7%)Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: −$907.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $142.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure(25.6%)Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: −$260.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Revenue: $1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure(126.4%)Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: −$857.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Revenue: $678.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(356.8%)Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: −$1.39bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Revenue: $389.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(562.1%)Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: −$815.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure
Net margin%0.7%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $13.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Revenue: $1.86bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure(115.9%)Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: −$1.12bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Revenue: $966.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(899.1%)Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: −$971.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Revenue: $108.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(581.0%)Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: −$825.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $142.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure(19.7%)Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: −$200.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Revenue: $1.02bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figure(121.8%)Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: −$826.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Revenue: $678.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(345.2%)Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: −$1.34bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Revenue: $389.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(539.3%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$782.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Revenue: $145.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure
Diluted EPS$ per share0.03Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figurenot reported (Diluted EPS not reported)(2.52)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$2.52 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(2.13)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$2.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure(0.51)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.51 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-06, accession 0001682852-25-000075.Report this figurenot reported (Diluted EPS not reported)(3.40)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$3.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(1.97)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$1.97 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-31, accession 0001682852-26-000150.Report this figure
Free cash flow$m(1,717)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$1.57bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001682852-25-000075. Derived: 9-month figure less the 6-month figure.Capital expenditure: $151.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001682852-25-000075. Derived: 9-month figure less the 6-month figure.Report this figure303Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $825.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Capital expenditure: $522.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(1,154)Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: −$1.04bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Capital expenditure: $117.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(922)Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: −$919.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Capital expenditure: $3.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Report this figure(880)Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: −$847.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001682852-25-000075. Derived: 9-month figure less the 6-month figure.Capital expenditure: $33.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001682852-25-000075. Derived: 9-month figure less the 6-month figure.Report this figure891Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $930.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Capital expenditure: $39.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001682852-26-000033. Derived: 12-month figure less the 9-month figure.Report this figure(692)Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: −$630.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Capital expenditure: $62.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-01, accession 0001682852-26-000060.Report this figure(563)Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: −$526.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Capital expenditure: $37.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-31, accession 0001682852-26-000150. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$1.94bnOperating margin −158.1%
Diluted EPS−$7.26, FY2025
Free cash flow−$2.06bn, FY2025
Moderna, Inc., key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn18.5Revenue, FY2021, twelve months to 2021-12-31$18.47bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001682852-24-000015.Report this figure19.3Revenue, FY2022, twelve months to 2022-12-31$19.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001682852-25-000022.Report this figure6.8Revenue, FY2023, twelve months to 2023-12-31$6.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure3.2Revenue, FY2024, twelve months to 2024-12-31$3.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure1.9Revenue, FY2025, twelve months to 2025-12-31$1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%72.0%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $13.30bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-23, accession 0001682852-24-000015.Revenue: $18.47bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001682852-24-000015.Report this figure48.9%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $9.42bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-21, accession 0001682852-25-000022.Revenue: $19.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001682852-25-000022.Report this figure(61.9%)Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: −$4.24bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $6.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(121.9%)Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: −$3.94bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $3.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(158.1%)Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: −$3.07bn. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure
Net margin%66.1%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $12.20bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-23, accession 0001682852-24-000015.Revenue: $18.47bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-23, accession 0001682852-24-000015.Report this figure43.4%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $8.36bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-21, accession 0001682852-25-000022.Revenue: $19.26bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-21, accession 0001682852-25-000022.Report this figure(68.8%)Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: −$4.71bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $6.85bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(110.0%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$3.56bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $3.24bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(145.2%)Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: −$2.82bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-20, accession 0001682852-26-000033.Revenue: $1.94bn. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure
Diluted EPS$ per share28.29Diluted EPS, FY2021, twelve months to 2021-12-31$28.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-23, accession 0001682852-24-000015.Report this figure20.12Diluted EPS, FY2022, twelve months to 2022-12-31$20.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-21, accession 0001682852-25-000022.Report this figure(12.33)Diluted EPS, FY2023, twelve months to 2023-12-31−$12.33 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(9.28)Diluted EPS, FY2024, twelve months to 2024-12-31−$9.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(7.26)Diluted EPS, FY2025, twelve months to 2025-12-31−$7.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure
Free cash flow$bn13.3Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $13.62bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-23, accession 0001682852-24-000015.Capital expenditure: $284.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-23, accession 0001682852-24-000015.Report this figure4.6Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $4.98bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-21, accession 0001682852-25-000022.Capital expenditure: $400.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-21, accession 0001682852-25-000022.Report this figure(3.8)Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: −$3.12bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001682852-26-000033.Capital expenditure: $707.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(4.1)Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: −$3.00bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001682852-26-000033.Capital expenditure: $1.05bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure(2.1)Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: −$1.87bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-20, accession 0001682852-26-000033.Capital expenditure: $192.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-20, accession 0001682852-26-000033.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Moderna, Inc.
FundQuarter endedReported valueSharesPut or callChange on the quarter before
FMR LLC2026-06-30$3.63bn51,859,891Added+6,187,867
BlackRock, Inc.2026-06-30$2.14bn30,599,409Added+963,533
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$1.63bn23,208,792Added+336,334
Capital World Investors2026-06-30$1.56bn22,276,996Added+3,579,302
BAILLIE GIFFORD & CO2026-06-30$1.28bn18,206,778Reduced−1,779,098
STATE STREET CORP2026-06-30$1.10bn15,726,193Added+864,784
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$1.09bn15,581,313Reduced−35,054
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$678.8m9,710,335Added+275,203
MORGAN STANLEY2026-06-30$668.0m9,538,094Added+1,066,831
Theleme Partners LLP2026-06-30$564.3m8,057,571Added+9,326

Recent filings

All 1,496 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Moderna, Inc., recent filings
FiledFormWhat it isAccession number
2026-09-3011:15 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001193125-26-408289
2026-09-0120:37 ET8-K1.01 Entry into a material agreement; 2.03 New direct financial obligation; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits0001193125-26-378505
2026-07-3120:17 ET10-QQuarterly reportPeriod 2026-06-300001682852-26-000150
2026-07-3111:03 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001682852-26-000147
2026-07-0811:08 ET8-K5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001682852-26-000134
2026-05-1110:06 ET8-K5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits0001682852-26-000101
2026-05-0120:10 ET10-QQuarterly reportPeriod 2026-03-310001682852-26-000060
2026-05-0110:32 ET8-K2.02 Results of operations; 9.01 Financial statements and exhibits0001682852-26-000057
2026-03-1620:31 ETDEF 14AProxy statementPeriod 2026-05-060001308179-26-000081
2026-03-0501:20 ET8-K1.01 Entry into a material agreement0001682852-26-000047

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 20, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1682852
Tickers
MRNA
Exchange
Nasdaq
SIC code
2836 Biological Products, (No Diagnostic Substances)
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer
Former names
Moderna Therapeutics, Inc. (to 2016-08-24)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:46 ET. Listed shows no prices and gives no investment advice.